An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Disease Sites:

Miscellaneous

Staging:

Phase I

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Carboplatin, Cisplatin, LY4050784, Nab-Paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed

Principal Investigator(s):

Davis, Elizabeth

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

10-20-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTPHI24160

National Clinical Trial ID:

NCT06561685

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available